Goldman Sachs’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $11.8M | Buy |
|
|||||
|
2025
Q1 | $7.55M | Buy |
|
|||||
|
2024
Q4 | $8.48M | Buy |
|
|||||
|
2024
Q3 | $20.7M | Sell |
|
|||||
|
2024
Q2 | $23.8M | Buy |
|
|||||
|
2024
Q1 | $17.1M | Buy |
|
|||||
|
2023
Q4 | $8.15M | Buy |
|
|||||
|
2023
Q3 | $3.19M | Buy |
|
|||||
|
2023
Q2 | $2.97M | Buy |
|
|||||
|
2023
Q1 | $2.66M | Sell |
|
|||||
|
2022
Q4 | $7M | Sell |
|
|||||
|
2022
Q3 | $6.63M | Buy |
|
|||||
|
2022
Q2 | $4.09M | Buy |
|
|||||
|
2022
Q1 | $6.95M | Buy |
|
|||||
|
2021
Q4 | $6.98M | Buy |
|
|||||
|
2021
Q3 | $2.05M | Buy |
|
|||||
|
2021
Q2 | $954K | Buy |
|
|||||
|
2021
Q1 | $392K | Sell |
|
|||||
|
2020
Q4 | $8.74M | Buy |
|
|||||
|
2020
Q3 | $683K | Buy |
|